Selected as Technology Pioneer in 2008 by the World Economic Forum, Anecova is reinforcing its Executive Team by appointing Dr. Peter Svalander as Chief Scientific Officer.
Martin Velasco, Founder, Chairman and CEO of Anecova, said “we are delighted to welcome Peter Svalander as our new Chief Scientific Officer. Being the founder and former CEO of Vitrolife, he is a recognized pioneer in embryology and the IVF field. He brings a unique expertise, both in the clinical treatment of infertile patients, and on the research and innovation side, especially in relation to fertilisation and early embryo development, which are instrumental to capture the full potential of Anecova natural procedures.
“I am delighted to join Anecova as CSO, a technology pioneering company that, in the field of fertility treatment, has the woman’s fertility well-being at the core of its innovation. A device and procedure that can bring conception within the natural female environment will be beneficial to the prospective parents and potentially also to the children conceived through IVF technology” said Peter Svalander.
About Dr. Peter Svalander
Dr. Peter Svalander received his medical degree at Uppsala University and is Associate Professor of experimental OB/GYN at Gothenburg University Sweden as well as Clinical Scientist (Hon) at King’s College Hospital London and Board-Certified in the USA. He has worked in the field of IVF for over 30 years, developing an outstanding experience as scientist, clinician, R&D Director and innovator, combined with commercial experience from several IVF start-up’s including Vitrolife AB and Progyny Inc. (formerly Auxogyn Inc.).
Anecova is a Swiss medical device company based at the EPFL Innovation Park in Lausanne. Anecova is working with world leading scientists and clinicians in the area of Assisted Reproductive Technology (ART) with the objective of developing more natural approach estoART. The company is ISOcertified (9001 and13485) and its AneVivo device is European Certified (CEMARK) and has also received the approval of several regulators in Europe, including the HFEA in the UK. Anecova has been working during recent years in the development of a device allowing the fertilisation and embryo development in the maternal environment instead of in the IVF laboratory. AneVivo, its first device, allows clinics to offer a Natural Fertilisation and very early development procedure to their patients. Anecova is starting the commercialisation of AneVivo through a selected group of leading IVF clinics in Europe. Anecova was granted the Technology Pioneer Award in 2008 at the World Economic Forum. For more information go to www.anecova.com.
For further information, please contact:
+41 21 353 57 90
+41 22 591 22 63